Extensive thromboembolic event as initial presentation of monoclonal gammopathy of undetermined significance

Marc Righini; Françoise Boehlen; Salah Gueddi; Grégoire Le Gal; Philippe de Moerloose

doi:10.1160/TH06-02-0123

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2006; 96(01): 93-94
DOI: 10.1160/TH06-02-0123

Case Report

Schattauer GmbH

Extensive thromboembolic event as initial presentation of monoclonal gammopathy of undetermined significance

Marc Righini

¹Division of Angiology and Hemostasis, Department of Internal Medicine, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland

,

Françoise Boehlen

¹Division of Angiology and Hemostasis, Department of Internal Medicine, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland

,

Salah Gueddi

¹Division of Angiology and Hemostasis, Department of Internal Medicine, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland

,

Grégoire Le Gal

²Equipe d’accueil 3878 (GETBO) and Department of Internal Medicine and Chest Diseases, Brest University Hospital, France

,

Philippe de Moerloose

¹Division of Angiology and Hemostasis, Department of Internal Medicine, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland

› Author Affiliations

Abstract

Full Text

References

References
1 Crawford J, Eye MK, Cohen HJ. Evaluation of monoclonal gammopathies in the “well” elderly. Am J Med 1987; 82: 39-45.
2 Kyle RA, Therneau TM, Rajkumar SV. et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354: 1362-9.
3 Kyle RA, Therneau TM, Rajkumar SV. et al. A longterm study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346: 564-9.
4 Barlogie B, Jagannath S, Desikan KR. et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
5 Srkalovic G, Elson P, Trebisky B. et al. Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma. Med Oncol 2002; 19: 219-26.
6 Zangari M, Anaissie E, Barlogie B. et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98: 1614-5.
7 Zangari M, Siegel E, Barlogie B. et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002; 100: 1168-71.
8 Minnema MC, Fijnheer R, De Groot PG. et al. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 2003; 01: 445-9.
9 Sallah S, Husain A, Wan J. et al. The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann Oncol 2004; 15: 1490-4.
10 Srkalovic G, Cameron MG, Rybicki L. et al. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 2004; 101: 558-66.
11 White RH, Chew HK, Zhou H. et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 2005; 165: 1782-7.
12 Rajkumar SV, Kyle RA, Therneau TM. et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005; 106: 812-7.